€40M in Series C for a British Biotech Treating Blindness with Gene Therapy – Labiotech.eu (blog)
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the clinic, the company has closed a Series C round with $45M (€39.5M) that will go towards … |
